AAPL329.26+2.67 (+0.82%) ▲|ABBV255.55+2.17 (+0.86%) ▲|ABT100.86-0.81 (-0.79%) ▼|ACN141.15-3.59 (-2.48%) ▼|ADBE227.00-7.74 (-3.30%) ▼|AMAT565.50+39.80 (+7.57%) ▲|AMD535.45+31.88 (+6.33%) ▲|AMGN363.86-0.31 (-0.09%) ▼|AMT164.83-2.24 (-1.34%) ▼|AMZN247.42-2.57 (-1.03%) ▼|AVGO386.53+8.37 (+2.21%) ▲|AXP351.58-0.36 (-0.10%) ▼|BA210.55+1.07 (+0.51%) ▲|BAC61.37+0.95 (+1.56%) ▲|BKNG177.31-2.14 (-1.19%) ▼|BLK1,053.64-0.48 (-0.05%) ▼|BMY60.48+0.32 (+0.52%) ▲|BNY158.51+1.58 (+1.01%) ▲|BRK-B490.29-0.96 (-0.20%) ▼|C133.18+4.46 (+3.46%) ▲|CAT891.56+27.26 (+3.15%) ▲|CL90.20-1.74 (-1.89%) ▼|CMCSA23.69-0.10 (-0.40%) ▼|COF206.01-0.77 (-0.37%) ▼|COP116.99+1.31 (+1.13%) ▲|COST928.96-6.84 (-0.73%) ▼|CRM169.96-3.83 (-2.20%) ▼|CSCO111.18+0.48 (+0.43%) ▲|CVS109.45+1.84 (+1.71%) ▲|CVX190.07+0.36 (+0.19%) ▲|DE593.14+7.14 (+1.22%) ▲|DHR174.59-26.53 (-13.19%) ▼|DIS96.53+0.12 (+0.12%) ▲|DUK125.08-0.77 (-0.61%) ▼|EMR139.51+2.93 (+2.15%) ▲|FDX314.61+8.39 (+2.74%) ▲|GD370.74+0.14 (+0.04%) ▲|GE342.27+0.97 (+0.28%) ▲|GEV1,089.99+10.81 (+1.00%) ▲|GILD129.68-3.53 (-2.65%) ▼|GM78.91+3.11 (+4.10%) ▲|GOOG348.66-2.71 (-0.77%) ▼|GOOGL349.28-2.71 (-0.77%) ▼|GS1,080.93+25.90 (+2.45%) ▲|HD331.80-1.24 (-0.37%) ▼|HON231.64+5.46 (+2.41%) ▲|IBM211.01-1.99 (-0.93%) ▼|INTC104.36+7.30 (+7.52%) ▲|INTU289.56-4.26 (-1.45%) ▼|ISRG356.94+3.77 (+1.07%) ▲|JNJ250.61+1.79 (+0.72%) ▲|JPM344.94+6.07 (+1.79%) ▲|KO82.03-0.09 (-0.11%) ▼|LIN505.31-6.74 (-1.32%) ▼|LLY1,162.85+15.95 (+1.39%) ▲|LMT505.53-4.01 (-0.79%) ▼|LOW203.87-0.85 (-0.41%) ▼|LRCX322.12+15.36 (+5.01%) ▲|MA541.38-6.07 (-1.11%) ▼|MCD264.64-3.00 (-1.12%) ▼|MDLZ59.68-0.59 (-0.98%) ▼|MDT82.64-0.65 (-0.78%) ▼|META647.27+1.42 (+0.22%) ▲|MMM172.69+13.58 (+8.54%) ▲|MO73.48-1.18 (-1.58%) ▼|MRK125.55+1.15 (+0.92%) ▲|MS215.95+5.01 (+2.38%) ▲|MSFT397.87-4.43 (-1.10%) ▼|MU969.77+104.31 (+12.05%) ▲|NEE87.81-0.20 (-0.22%) ▼|NFLX66.85-0.75 (-1.11%) ▼|NKE43.26-0.22 (-0.49%) ▼|NOW102.24-2.46 (-2.35%) ▼|NVDA205.70+2.42 (+1.19%) ▲|ORCL125.49+4.11 (+3.38%) ▲|PEP134.61-0.86 (-0.63%) ▼|PFE24.89+0.14 (+0.55%) ▲|PG147.55-1.58 (-1.06%) ▼|PLTR133.37-1.48 (-1.10%) ▼|PM190.51-2.21 (-1.15%) ▼|QCOM174.23+3.91 (+2.30%) ▲|RTX196.40+1.96 (+1.01%) ▲|SBUX104.96+0.15 (+0.14%) ▲|SCHW102.57+0.03 (+0.03%) ▲|SO93.55-0.91 (-0.96%) ▼|SPG227.93-0.27 (-0.12%) ▼|T21.99+0.04 (+0.18%) ▲|TMO518.64-7.60 (-1.44%) ▼|TMUS191.19-4.45 (-2.27%) ▼|TSLA380.96+11.39 (+3.08%) ▲|TXN294.51+10.44 (+3.68%) ▲|UBER71.53-0.65 (-0.89%) ▼|UNH433.68+12.13 (+2.88%) ▲|UNP294.85-1.40 (-0.47%) ▼|UPS116.08+2.93 (+2.59%) ▲|USB63.45+0.31 (+0.48%) ▲|V358.32-2.25 (-0.62%) ▼|VZ43.37-0.14 (-0.31%) ▼|WFC87.89+1.56 (+1.80%) ▲|WMT110.29-1.91 (-1.70%) ▼|XOM150.97+2.61 (+1.76%) ▲|AAPL329.26+2.67 (+0.82%) ▲|ABBV255.55+2.17 (+0.86%) ▲|ABT100.86-0.81 (-0.79%) ▼|ACN141.15-3.59 (-2.48%) ▼|ADBE227.00-7.74 (-3.30%) ▼|AMAT565.50+39.80 (+7.57%) ▲|AMD535.45+31.88 (+6.33%) ▲|AMGN363.86-0.31 (-0.09%) ▼|AMT164.83-2.24 (-1.34%) ▼|AMZN247.42-2.57 (-1.03%) ▼|AVGO386.53+8.37 (+2.21%) ▲|AXP351.58-0.36 (-0.10%) ▼|BA210.55+1.07 (+0.51%) ▲|BAC61.37+0.95 (+1.56%) ▲|BKNG177.31-2.14 (-1.19%) ▼|BLK1,053.64-0.48 (-0.05%) ▼|BMY60.48+0.32 (+0.52%) ▲|BNY158.51+1.58 (+1.01%) ▲|BRK-B490.29-0.96 (-0.20%) ▼|C133.18+4.46 (+3.46%) ▲|CAT891.56+27.26 (+3.15%) ▲|CL90.20-1.74 (-1.89%) ▼|CMCSA23.69-0.10 (-0.40%) ▼|COF206.01-0.77 (-0.37%) ▼|COP116.99+1.31 (+1.13%) ▲|COST928.96-6.84 (-0.73%) ▼|CRM169.96-3.83 (-2.20%) ▼|CSCO111.18+0.48 (+0.43%) ▲|CVS109.45+1.84 (+1.71%) ▲|CVX190.07+0.36 (+0.19%) ▲|DE593.14+7.14 (+1.22%) ▲|DHR174.59-26.53 (-13.19%) ▼|DIS96.53+0.12 (+0.12%) ▲|DUK125.08-0.77 (-0.61%) ▼|EMR139.51+2.93 (+2.15%) ▲|FDX314.61+8.39 (+2.74%) ▲|GD370.74+0.14 (+0.04%) ▲|GE342.27+0.97 (+0.28%) ▲|GEV1,089.99+10.81 (+1.00%) ▲|GILD129.68-3.53 (-2.65%) ▼|GM78.91+3.11 (+4.10%) ▲|GOOG348.66-2.71 (-0.77%) ▼|GOOGL349.28-2.71 (-0.77%) ▼|GS1,080.93+25.90 (+2.45%) ▲|HD331.80-1.24 (-0.37%) ▼|HON231.64+5.46 (+2.41%) ▲|IBM211.01-1.99 (-0.93%) ▼|INTC104.36+7.30 (+7.52%) ▲|INTU289.56-4.26 (-1.45%) ▼|ISRG356.94+3.77 (+1.07%) ▲|JNJ250.61+1.79 (+0.72%) ▲|JPM344.94+6.07 (+1.79%) ▲|KO82.03-0.09 (-0.11%) ▼|LIN505.31-6.74 (-1.32%) ▼|LLY1,162.85+15.95 (+1.39%) ▲|LMT505.53-4.01 (-0.79%) ▼|LOW203.87-0.85 (-0.41%) ▼|LRCX322.12+15.36 (+5.01%) ▲|MA541.38-6.07 (-1.11%) ▼|MCD264.64-3.00 (-1.12%) ▼|MDLZ59.68-0.59 (-0.98%) ▼|MDT82.64-0.65 (-0.78%) ▼|META647.27+1.42 (+0.22%) ▲|MMM172.69+13.58 (+8.54%) ▲|MO73.48-1.18 (-1.58%) ▼|MRK125.55+1.15 (+0.92%) ▲|MS215.95+5.01 (+2.38%) ▲|MSFT397.87-4.43 (-1.10%) ▼|MU969.77+104.31 (+12.05%) ▲|NEE87.81-0.20 (-0.22%) ▼|NFLX66.85-0.75 (-1.11%) ▼|NKE43.26-0.22 (-0.49%) ▼|NOW102.24-2.46 (-2.35%) ▼|NVDA205.70+2.42 (+1.19%) ▲|ORCL125.49+4.11 (+3.38%) ▲|PEP134.61-0.86 (-0.63%) ▼|PFE24.89+0.14 (+0.55%) ▲|PG147.55-1.58 (-1.06%) ▼|PLTR133.37-1.48 (-1.10%) ▼|PM190.51-2.21 (-1.15%) ▼|QCOM174.23+3.91 (+2.30%) ▲|RTX196.40+1.96 (+1.01%) ▲|SBUX104.96+0.15 (+0.14%) ▲|SCHW102.57+0.03 (+0.03%) ▲|SO93.55-0.91 (-0.96%) ▼|SPG227.93-0.27 (-0.12%) ▼|T21.99+0.04 (+0.18%) ▲|TMO518.64-7.60 (-1.44%) ▼|TMUS191.19-4.45 (-2.27%) ▼|TSLA380.96+11.39 (+3.08%) ▲|TXN294.51+10.44 (+3.68%) ▲|UBER71.53-0.65 (-0.89%) ▼|UNH433.68+12.13 (+2.88%) ▲|UNP294.85-1.40 (-0.47%) ▼|UPS116.08+2.93 (+2.59%) ▲|USB63.45+0.31 (+0.48%) ▲|V358.32-2.25 (-0.62%) ▼|VZ43.37-0.14 (-0.31%) ▼|WFC87.89+1.56 (+1.80%) ▲|WMT110.29-1.91 (-1.70%) ▼|XOM150.97+2.61 (+1.76%) ▲|
24.8 C
New York
Tuesday, July 21, 2026

Tag: artery

newssourceFORcompanyinformationcontent1releasesmarket

Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and...

Bagsværd, Denmark, 23 June 2025 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Ozempic® (once-weekly semaglutide) label to reflect the positive data from the STRIDE peripheral artery disease (PAD) functional outcomes trial.

Semaglutide Increases Walking Capacity in Patients with Peripheral Artery Disease and Type 2 Diabetes

Common obesity drug reduced the risk of disease progression by 54% CHICAGO, June 21, 2025 /PRNewswire/ -- Today, a new analysis demonstrates the vascular...

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at...

Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with muscle preservation

Port of L.A. Rollercoaster: Thank Trump’s Economic Masterpiece

Ah, the Port of Los Angeles, a once-thrumming artery of global commerce, now finds itself in a state of eerie tranquility. Towering cranes that...

MedHub-AI Receives PMDA Approval in Japan for AutocathFFR®

TEL AVIV, Israel, June 18, 2025 /PRNewswire/ -- MedHub-AI, a global leader in AI-powered cardiovascular diagnostics, announced today that the Pharmaceuticals and Medical Devices Agency...

Critical Limb Ischemia Treatment Market to Reach USD 10.02 Billion by 2032, Owing to Rising Demand for Minimally Invasive Vascular Therapies | Coherent Market...

Burlingame, CA, June 18, 2025 (GLOBE NEWSWIRE) -- The Coherent Market Insights reveals that the Critical Limb Ischemia Treatment Market is estimated to be valued at USD 5.55 Bn in 2025 and is expected to reach USD 10.02 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 8.8% from 2025 to 2032. The critical limb ischemia treatment market is projected to experience significant growth during the forecast period. Key factors driving this expansion include the increasing global geriatric population and the rising prevalence of peripheral artery disease, both of which are contributing to a growing demand for effective treatment options.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsArtery

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers